Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, these key aspartate-producing players are specifically repressed in VHL-deficient human renal carcinomas, a paradigmatic tumor type in which HIF1α acts as a tumor suppressor, highlighting the in vivo relevance of these findings.
|
30811976 |
2019 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
VHL inactivation is a key oncogenic event for renal carcinomas.
|
30006568 |
2018 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Most of the clear cell carcinomas (sporadic as well as familial) have mutations and deletions in the VHL gene located at 3p (p3.25).
|
29465421 |
2018 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We report a case of a female patient of 37 years diagnosed VHL and intervened on several occasions by cerebral hemangioblastoma and renal carcinomas.
|
27055912 |
2017 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
While the inactivation of VHL gene can be found in the majority of clear cell carcinomas, different molecular mechanisms are involved into pRCC biology.
|
26052049 |
2015 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The prevalence of TP53 mutations in relation to VHL status may differ between clear-cell and other renal carcinomas.
|
20137853 |
2010 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Somatic VHL mutations are also common in sporadic clear cell renal carcinomas.
|
17255293 |
2007 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Molecular and genetic studies have identified functional loss of the von Hippel-Lindau (VHL) gene as a frequent and crucial event in the development of the malignant phenotype of clear cell renal carcinomas.
|
17575159 |
2007 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Inactivation of the VHL gene is responsible for the autosomal dominant condition von Hippel-Lindau (VHL) disease and is implicated in most sporadic clear cell renal carcinomas.
|
16775032 |
2006 |
Carcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency.
|
16061637 |
2005 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The far lower frequency of clear cell carcinomas and VHL alterations compared with adults suggests that renal cell carcinomas in young patients have a unique genetic background.
|
15316311 |
2004 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Loss of von Hippel-Lindau (VHL) protein function results in an autosomal-dominant cancer syndrome known as VHL disease, which manifests as angiomas of the retina, hemangioblastomas of the central nervous system, renal clear-cell carcinomas and pheochromocytomas.
|
15162797 |
2004 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
To address the aberrant promoter methylation profiles of MSI-H gastric carcinomas, promoter methylation of six genes (hMLH1, p16(INK4A), E-cadherin, Rb, RASSF1A, and VHL) and CpG island methylator phenotype (CIMP) were explored in 36 MSI-H gastric carcinomas and the results were compared with those of 43 microsatellite-stable (MSS) gastric carcinomas.
|
12692837 |
2003 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene (VHL) is linked to the development of hereditary (VHL-associated) and sporadic clear-cell renal carcinomas as well as other abnormalities.
|
14691554 |
2003 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Somatic mutations of the VHL gene were detected only in clear cell renal carcinomas that overexpressed HIF-1alpha.
|
11431362 |
2001 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We semiquantitatively analyzed 29 renal carcinomas (22 clear cell, 5 chromophilic, 2 chromophobic tumors) for VHL mRNA, and VEGF expression for morphology and tumor size.
|
10475065 |
1999 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Inherited and sporadic clear cell renal carcinomas are characterized by inactivation of both copies of the VHL gene by mutation, and/or by hypermethylation.
|
9140397 |
1997 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Approximately 57% of all renal carcinomas of the clear cell type analyzed revealed a mutation in the von Hippel-Lindau disease (VHL) gene.
|
9059819 |
1997 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The von Hippel-Lindau tumor suppressor gene at 3p25-26 is found to be mutated in the nondeleted allele in 57% of these sporadic clear cell carcinomas.
|
8959640 |
1996 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The authors have analyzed VHL gene alterations on chromosome 3p in sporadic human colon carcinomas and adenomas using modified microdissection techniques.
|
8617456 |
1996 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Clear cell renal carcinomas are most frequently characterized by loss of function of both copies of the von Hippel-Lindau (VHL) disease gene, suggesting that the VHL gene product plays an important role in regulating renal cell proliferation.
|
7585510 |
1995 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Mutational inactivation and allelic loss of the von Hippel-Lindau (VHL) gene appear to be causal events for the majority of spontaneous clear-cell renal carcinomas.
|
7937876 |
1994 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The identification of VHL mutations in a majority of localized and advanced sporadic renal carcinomas and in a second form of hereditary renal carcinoma indicates that the VHL gene plays a critical part in the origin of this malignancy.
|
7915601 |
1994 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In addition, loss of heterozygosity of the VHL gene was observed in 16 (84%) of 19 informative clear cell renal carcinomas.
|
8187067 |
1994 |